Benchmark International is pleased to announce the acquisition of Glasgow-based Community Pharmacology Services (CPS Research) by FutureMeds.
CPS Research conducts phase II-IV clinical trials and has over 30 years of clinical research experience. With a reach throughout the central belt of Scotland, the CPS team has conducted over 250 studies across a wide range of therapeutic areas and indications, such as cardiology, endocrinology, gastroenterology, gynaecology, orthopaedics, psychiatry, immunology, dermatology, and respiratory medicine.
FutureMeds is the first European dedicated decentralised clinical trial (DCT) site network. Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.
This expansion promises to bring enhanced solutions to clients and accelerated access to new treatments for patients. CPS Research has over 4,000 engaged patients in the database, and with the FutureMeds DCT toolkit, the catchment area can be extended over the Glasgow urban area.
Post acquisition, co-founders of CPS Research, Dr Alan Wade MBCHB FRCA and Dr Gordon Crawford BSC MBCHB MRCGP, will embark on a new chapter within a year, while general manager, Craig McCallum, will continue to lead the research team. His goal is to expand the team's relationships with local communities, amplify the site’s impact in driving medical progress and improve patients' access to new treatments.
Mr McCallum said: “As we bring together our wealth of experience to the ultimate benefit of our clients and patients, we are truly excited for the future and what we will be able to achieve as part of such a growing powerhouse of medical research.”
Dr Crawford added: "Having developed CPS Research with Alan, we are delighted to see it become part of the growing FutureMeds Site Network. By contributing to medical progress, we are sure CPS Research's team will build on our legacy and continue to thrive as one of the best dedicated research centres in the UK."
John Allen, managing director at FutureMeds commented: “The addition of CPS Research marks a significant milestone for our clients, volunteers and teams. CPS Research has a reputable standing in the industry, boasting over three decades of expertise overseeing and conducting clinical trials. We are thrilled to welcome their knowledgeable team into our fold.”
Europe: Michael Lawrie at +44 (0) 161 359 4400 / Lawrie@BenchmarkIntl.com
Americas: Sam Smoot at +1 (813) 898 2350 / Smoot@BenchmarkIntl.com
Africa: Anthony McCardle at +27 21 300 2055 / McCardle@BenchmarkIntl.com
ABOUT BENCHMARK INTERNATIONAL:
Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $10 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive M&A Advisor in the World by Pitchbook’s Global League Tables.